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Introduction
Ifosfamide is an alkylating agent frequently used to treat ovarian, tes-
ticular, cervical, and head and neck cancers, as well as lymphomas and
soft tissue sarcomas. Frequent side effects of ifosfamide include myelo-
toxicity, hemorrhagic cystitis and neurotoxicity (mental confusion, drowsi-
ness, hallucinations, disorientation, and coma) [1]. Although the use of
ifosfamide was initially limited by severe hemorrhagic cystitis, this prob-
lem was resolved by the concurrent administration of sodium 2-mercap-
toethane sulfonate (mesna), a synthetic thiol compound that binds to toxic
species of ifosfamide in the bladder to form stable nontoxic thioether com-
pounds. Ifosfamide and mesna can both have adverse effects in the central
nervous system (CNS), with 10-30% of ifosfamide-treated patients ex-
periencing CNS toxicity [2-6]. These neurotoxicities are dose dependent
and may be fatal. Furthermore, the mechanism of action and factors pre-
disposing to ifosfamide-induced encephalopathy are poorly understood.
Methylene blue (MB) can be used to treat these encephalopathies, but its
mechanism of action is unclear. In this report, we describe two patients
with recurrent epithelial ovarian cancer who experienced fatal ifosfamide-
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Central nervous system (CNS) toxicity has been reported in approximately 10-30% of patients re-
ceiving intravenous infusions of ifosfamide. Encephalopathy is a rare but serious CNS adverse
reaction in these patients, and although usually transient and reversible, may cause persistent
neurological dysfunction or death. Clinical features range from fatigue and confusion to coma
and death. Although methylene blue can be used to treat ifosfamide-induced neurotoxicity, in-
cluding encephalopathy, its mechanism of action remains poorly defined. We describe here two
patients with recurrent epithelial ovarian cancer who experienced fatal encephalopathy following
ifosfamide/mesna treatment.
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induced encephalopathy, as well as a review of the proposed pathophys-
iology of ifosfamide-induced encephalopathy and the use of MB in its
management.
C ase  R e por ts
1. Case 1   
A 54-year-old, gravida 2, para 2, married woman presented with re-
current epithelial ovarian cancer (endometrioid adenocarcinoma). She had
noninsulin dependent diabetes mellitus, diabetic retinopathy, and hyper-
tension. Seven years earlier, she underwent coronary artery bypass grafting
due to coronary artery disease. 
Three years ago, she was transferred to our center after laparoscopic
bilateral salpingo-oophorectomy which led to a diagnosis of epithelial
ovarian cancer. She underwent a debulking operation, including total ab-
dominal hysterectomy and pelvic and paraaortic lymph node dissection,
total omentectomy, appendectomy, peritoneal mass excision, and left
ureter resection and anastomosis. The tumor was categorized as Interna-
tional Federation of Obstetrics and Gynecology (FIGO) stage IIIc and cy-
toreductive surgery was suboptimal. Following the surgery, she received
6 cycles of adjuvant chemotherapy with paclitaxel/carboplatin. However,
because there was disease progression in this patient, she was further
treated with 3 cycles of topotecan, followed by 3 cycles of docetaxel. An
abdomino-pelvic computed tomography (CT) scan showed aggravation
of disease and her serum carbohydrate antigen 125 (CA-125) concentra-
tion was elevated from 534 to 1,270 U/mL. We decided to change her
chemotherapy regimen to ifosfamide monotherapy. 
She was started on ifosfamide 1,200 mg/m2/day, administered via con-
tinuous infusion on days 1-3 of each 4 week cycle, along with mesna 300
mg/m2/day. On the third day she received ifosfamide, her mental status
worsened, with a change from drowsiness to stupor, followed by disori-
entation, stereotyped movements, and emotional instability. She had no
lateralizing neurologic signs. Her blood test results, including measure-
ments of serum glucose, brain natriuretic peptide, and electrolytes, were
normal, and her cerebrospinal fluid was negative for malignant cells. In
addition, brain magnetic resonance imaging (MRI) findings were normal.
An electroencephalogram showed frequent 1-1.5 Hz periodic or single
triphasic waves on both hemispheres (Fig. 1). She was diagnosed with
ifosfamide-induced encephalopathy, and her chemotherapy was discon-
tinued immediately. Her neurologic symptoms and signs did not improve.
Despite the supportive care, her encephalopathy became aggravated, and
she developed ifosfamide-induced acute tubular necrosis. She was dis-
charged without any hope for recovery and died within 1 month. 
2. Case 2
A 46-year-old, gravida 2, para 2, married woman with recurrent ep-
ithelial ovarian cancer (serous adenocarcinoma) was referred to our insti-
tution for further management. She had no specific medical history. 
At initial diagnosis of epithelial ovarian cancer, she underwent bilateral
salpingo-oophorectomy, partial omentectomy and incidental appendec-
tomy at another hospital, and cytoreductive surgery was suboptimal. She
received 12 cycles of adjuvant chemotherapy with paclitaxel and carbo-
platin. However, an abdomino-pelvic CT scan showed residual peritoneal
carcinomatosis and her serum CA-125 concentration was elevated, from
517 to 1,020 U/mL. After referral to our center, she underwent optimal
cytoreductive surgery, including total abdominal hysterectomy, pelvic and
paraaortic lymph node dissection, low anterior resection, and right di-
aphragmatic stripping. After surgery, she received 3 cycles of adjuvant
chemotherapy with topotecan and cisplatin. Due to disease progression,
her regimen was switched to 3 cycles of docetaxel and carboplatin. Due
to the disease progression on this regimen, we changed her chemotherapy
regimen to a combination of ifosfamide and etoposide. She received the
first cycle of etoposide (75 mg/m2/day in 3-hour infusions on days 1-5)
and ifosfamide (1,200 mg/m2/day in 3-hour infusions on days 1-5), along
with 300 mg/m2/day mesna, without any complications. On day 6, her
speech became unintelligible but her orientation was intact. On day 7, she
developed delirium, disorientation, visual and auditory hallucinations,
stereotyped movements, and emotional instability. At that time, her esti-
mated glomerular filtration rate, serum creatinine and blood urea nitrogen
were 27 mL/min (normal, ＞60 mL/min), 2.3 mg/dL (normal, 0.7 to 1.4
mg/dL) and 33 mg/dL (normal, 10 to 26 mg/dL), respectively, and her
renal function decreased gradually. Brain MRI was normal. After referral
to a nephrologist, her electrolyte imbalance was corrected and her uremia
was improved by hemodialysis. However, her mental impairments
showed no improvement. She was diagnosed as having severe ifosfamide-
induced encephalopathy. She never recovered and was discharged in a
hopeless condition on day 10 and died within 1 month.
Discussio n
Ifosfamide is an oxazaphosphorine antineoplastic agent (a nitrogen
mustard derivative) and is a structural analog of cyclophosphamide [3,7].
Ifosfamide is a prodrug that requires hepatic activation to its cytotoxic
metabolite, ifosfamide mustard [7,8]. The latter is metabolized by cy-
tochrome p450 to generate the active alkylating agents, 4-hydroxy-ifos-
famide and isophosphoramide mustard [8]. Ifosfamide and its metabolites
can penetrate the blood brain barrier (BBB), with CNS toxicity occurring
in 10-40% of patients receiving high doses of the drug [2-6].
The exact pathophysiological mechanisms responsible for the devel-
opment of ifosfamide-induced encephalopathy are unclear, but one of the
causes is thought to be the dechloroethylation of Ifosfamide to form
chloroacetaldehyde (CAA) [8-10]. Hypotheses for the possible patho-
physiological pathways leading to the development of ifosfamide-induced
encephalopathy [2,11,12] were based on the finding of glutaric acid and
sarcosine in the urine of a patient with ifosfamide-induced encephalopathyCancer Res Treat. 2011;43(4):260-263
262 CANCER  RESEARCH AND  TREATMENT
(Fig. 2) [11,13]. The accumulation of glutaric acid may lead to an increase
in chloroethyl amine, the metabolism of which may in turn disturb the
mitochondrial respiratory chain. Thus, the accumulation of nicotinamide
adenine dinucleotide hydrogen (NADH) may prevent the dehydrogena-
tion of aldehydes such as the ifosfamide metabolite CAA, a potentially
neurotoxic substance [9]. CAA, which is structurally similar to both chlo-
ral hydrate and acetaldehyde, can cross the BBB and therefore be respon-
sible for ifosfamide-induced encephalopathy [7]. The neurotoxic effects
of CAA may be due to 1) a direct neurotoxic effect, 2) depletion from the
CNS of glutathione, and/or 3) the inhibition of mitochondrial oxidative
phosphorylation resulting in impaired fatty acid metabolism [2].
CNS toxicity displays a wide spectrum of signs and symptoms. Man-
ifestations of ifosfamide-induced encephalopathy include cerebellar
ataxia, mental confusion, complex visual hallucinations, extrapyramidal
signs, seizures and/or mutism. Less common CNS manifestations of ifos-
famide are asterixis, nonconvulsive status epilepticus, manic episodes and
cerebellar and temporo-frontal cortical degeneration [6].
According to the National Cancer Institute Toxicity Grading for En-
cephalopathy [14], there are five grades of encephalopathy. Most patients
with ifosfamide-induced encephalopathy show grade 1 or 2 symptoms.
Many patients with ifosfamide-induced encephalopathy recover sponta-
neously and completely within 48-72 hours following the onset of dis-
continuation  of  ifosfamide  and  conservative  management  such  as
adequate hydration. Some patients with ifosfamide-induced encephalopa-
thy present with grade 3 or 4 symptoms. However, most patients with
grade 3 or 4 symptoms can also recover spontaneously and completely.
In rare cases, grade 3 or 4 encephalopathy leads to death. Because ifos-
famide-induced encephalopathy research is limited to case reports and
small retrospective case series, the prognosis and sequelae according to
the toxicity grade, has not been clearly established [10].
Although factors predisposing to ifosfamide-induced encephalopathy
have not yet been revealed, rates of neurotoxicity may be increased by
pre-existing renal or hepatic failure, low albumin and poor performance
status [4,15]. These two cases were considered as grade 4 ifosfamide-in-
duced encephalopathy according to the National Cancer Institute Toxicity
Grading for Encephalopathy [14] and both resulted in death within 1
month. In case 1, the electroencephalogram (EEG) finding was also re-
vealed as Meanwell grade IV [5]. Both patients’ clinical courses may have
been aggravated by their decreased renal function [10]. 
Ifosfamide-induced encephalopathy is a clinical diagnosis. The differ-
ential diagnoses of ifosfamide-induced encephalopathy include infection,
metabolic abnormalities and concomitant drug-induced syndromes. It is
supported by normal brain imaging, EEG findings of metabolic en-
cephalopathy and the absence of other causes [6]. EEG characteristics
have been correlated with the clinical grading of ifosfamide-induced en-
cephalopathy [5]. For example, Meanwell grade 3 toxicity has been as-
sociated predominantly with delta wave activity, with or without sharp
complex waveforms, whereas patients with grade 4 toxicity exhibit con-
tinuous delta activity, complex waveforms and triphasic waves. The EEG
recording in case 1 showed evidence of grade 4 toxicity (Fig. 1). 
In patients experiencing acute ifosfamide-induced encephalopathy, the
mainstays of management include the prompt cessation of ifosfamide in-
fusion and intravenous hydration. Although ifosfamide-induced en-
cephalopathy usually reverses completely within 2-3 days after the
Fig. 1.  Electroencephalogram (EEG) recording in case 1, showing frequent diffuse 1 Hz periodic triphasic waves and rhythmic delta slowing
(EEG recording parameters: amplitude, 1 cm=70 ʼV; interval between two thick vertical lines=1 sec).You-Jung Shin, Ifosfamide-Induced Encephalopathy
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cessation of drug administration, it may not in some patients with high
grade toxicity. 
Because ifosfamide-induced encephalopathy can resolve sponta-
neously 48-72 hours following its onset, patients with mild symptoms
may not need treatment with MB. Patients with more severe symptoms
and with grade 3-4 toxicity may derive greater benefit from MB. How-
ever, as the encephalopathy resolves spontaneously in most cases, even
in patients with severe symptoms, and since controlled clinical trials have
not been conducted to determine the efficacy of MB in severe ifosfamide-
induced encephalopathy, the evidence to support its use is not strong [10].
In most cases, MB is considered for use in the management of acute
symptoms [12]. While some patients have experienced improvements in
CNS function as rapidly as within 10 minutes, others have required several
days to recover [10]. 
MB has been increasingly used both for the treatment and prevention
of ifosfamide-induced encephalopathy [8,11]. MB is thought to counteract
some of the metabolic pathways of ifosfamide [11]. It may act as an al-
ternative electron acceptor, replacing the inhibited flavoproteins and thus
restoring the mitochondrial respiratory chain. It may also oxidize NADH,
allowing the dehydrogenation of aldehydes. MB has also been found to
inhibit plasma and extrahepatic monoamine oxidases (Fig. 2) [3,8,13].
The recommended dose of intravenous MB for treatment of ifosfamide-
induced encephalopathy is 50 mg every 4 hours (1% aqueous solution
over 5 minutes), whereas the dose for secondary prophylaxis of ifos-
famide-induced encephalopathy is 50 mg every 6 hours, either intra-
venously or orally [8]. However, the efficacy of MB in patients with severe
ifosfamide-induced encephalopathy is still controversial.
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R efer ences
Fig. 2.  Proposed pathogenesis pathways involved in ifosfamide
neurotoxicity and the proposed sites of action of methylene blue: (1)
Inhibition of extrahepatic mono-amine oxidation of chloroethylamine
to chloroacetaldehyde; (2) Restoration of hepatic nicotinamide ade-
nine dinucleomide hydrogen (NADH) oxidative functions; (3) Sub-
stitute for electron transport flavoprotein (ETF) enzyme (electron
acceptor) (ada-pted from Donegan S. J Oncol Pharm Pract. 2001;
6:153-65 [13], with permission).